Sure, but Pharma A is full of career managers who never kill drugs under development and Upstart B relentlessly culls drugs that don't work early on. Upstart B's failure rate at the final stages is under 50% so they develop 5 times as many drugs, beating the existing company, and indeed all other drug companies.

Since this isn't happening, it seems this might not be the explanation.